Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 4/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21836163 | 1.00 | KMT2A (0.46) | KMT2ATLR2PTPN1MDM2 | |
| SCHEMBL26689778 | 1.00 | KMT2A (0.46) | KMT2ATLR2PTPN1MDM2 | |
| SCHEMBL26689395 | 1.00 | KMT2A (0.46) | KMT2ATLR2PTPN1MDM2 | |
| SCHEMBL30678132 | 1.00 | KMT2A (0.46) | KMT2ATLR2PTPN1MDM2 | |
| SCHEMBL16757551 | 1.00 | KMT2A (0.46) | KMT2ATLR2PTPN1MDM2 | |
| SCHEMBL30678112 | 1.00 | KMT2A (0.46) | KMT2ATLR2PTPN1MDM2 | |
| SCHEMBL26689398 | 1.00 | KMT2A (0.46) | KMT2ATLR2PTPN1MDM2 | |
| SCHEMBL29975272 | 1.00 | KMT2A (0.46) | KMT2ATLR2PTPN1MDM2 | |
| SCHEMBL16757654 | 0.93 | TLR2 (0.46) | KMT2ATLR2PTPN1MDM2 | |
| SCHEMBL31557564 | 0.93 | TLR2 (0.46) | KMT2ATLR2PTPN1MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | disclosed |
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023223097-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | KMT2A 719/4885TLR2 4179/4885PTPN1 1566/4885 |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | FCGR2A, FCGR3B, BCL3 | KMT2A 2434/4885TLR2 1153/4885PTPN1 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.